alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
MANDATE

Court of Appeals 

First District of Texas 

NO. 01-11-00352-CR

CURTIS LEE JOHNSON, Appellant

V.

THE STATE OF TEXAS, Appellee

Appeal from the 208th District Court of Harris County (Tr. Ct. No. 1178448).

TO THE 208th DISTRICT COURT OF HARRIS COUNTY, GREETINGS:

Before this Court, on the 4th day of November, 2014, the cause upon appeal to 

revise or to reverse your judgment was determined. This Court made its order in these 

words:

The cause heard today by the Court is an appeal from the judgment signed by the 

court below on October 19, 2009. After inspecting the record of the court below, it is the 

opinion of this Court that there is no reversible error in the judgment. It is therefore 

CONSIDERED, ADJUDGED, and ORDERED that the judgment of the court below be 

affirmed.

The Court orders that this decision be certified below for observance.

Judgment rendered November 4, 2014.
Per curiam opinion delivered by panel consisting of Justices Massengale, 

Brown, and Huddle.

WHEREFORE, WE COMMAND YOU to observe the order of our said Court 

in this behalf and in all things to have it duly recognized, obeyed, and executed.

January 23, 2015 

Date CHRISTOPHER A. PRINE

 CLERK OF THE COURT
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1318 Glucono delta-lactone. ( a ) Glucono delta-lactone (C6H10O6, CAS Reg. No. 90-80-2), also called *D*-gluconic acid delta-lactone or *D*-glucono-1,5-lactone, is the cyclic 1,5-intramolecular ester of *D*-gluconic acid. It is prepared by direct crystallization from the aqueous solution of gluconic acid. Gluconic acid may be produced by the oxidation of *D*-glucose with bromine water, by the oxidation of *D*-glucose by microorganisms that are nonpathogenic and nontoxicogenic to man or other animals, or by the oxidation of *D*-glucose with enzymes derived from these microorganisms.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 134, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a curing and pickling agent as defined in § 170.3(o)(5) of this chapter, leavening agent as defined in § 170.3(o)(17) of this chapter; pH control agent as defined in § 170.3(o)(23) of this chapter; and sequestrant as defined in § 170.3(o)(26) of this chapter.
( 2 ) The ingredient is used at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[51 FR 33896, Sept. 24, 1986]
### Adams, Kevin (OST)

From: 

### Sent: To: Cc.: 

### Subject: Ruby, Scott (CED) <scott.ruby@alaska.gov> Thursday, April18, 2013 2:25·PM Adams, Kevin (OST) Pearl Mikulski; Sewell, Richard E (DOD; Bourne, Pauletta A (CED) Diomede EAS Funding for SFY14 ........ ,.,.'

! ;:

Kevin, 

### 'c::;:; You inquired aboutthe status ofthe Diomede EAS match share funding forthe coming year. The legislature recently passed the state operating budget. Within the Department ofCommerce, Community, and Economic Development, Division ofCommunity and Regional Affairs funding in the amount of$200,000 was includedto provide 

### a grantto Kawerak, Inc for matching paymentfor the Diomede EAS contract. This is the same level offunding and underthe same terms as we are currently operating. This funding will be available for expenditures incurred from July 1, 2013 through June 30, 2014.

Ifyou have anyfurther questions, please let me know

Scott

### Sco.U~. Director Division of Community and Regional Affairs 550 W 7th Ave., Suite 1640 Anchorage, A K 99501 · Work: (907) 269-4569 Email: scott.ruby@alaska.gov
_________________________________________ 

 

 

Order Michigan Supreme Court

Lansing, Michigan 

October 27, 2008 Clifford W. Taylor,

 Chief Justice 

136528 Michael F. Cavanagh 

Elizabeth A. Weaver 

Marilyn Kelly 

Maura D. Corrigan 

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee, 

Robert P. Young, Jr. 

Stephen J. Markman, 

Justices 

v SC: 136528 

 COA: 282633 

Wayne CC: 04-003084-FH

THOMAS HENRY BLUMENTHAL III,

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the May 6, 2008 order of 

the Court of Appeals is considered, and it is DENIED, because the defendant has failed to 

meet the burden of establishing entitlement to relief under MCR 6.508(D). 

s1020 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

October 27, 2008 

 Clerk
# L_2019314EN.01017401.xml

| 5.12.2019 | EN | Official Journal of the European Union | L 314/174 |
| --- | --- | --- | --- |

5.12.2019

EN

Official Journal of the European Union

L 314/174

---

Corrigendum to Commission Implementing Decision (EU) 2019/1835 of 30 October 2019 excluding from European Union financing certain expenditure incurred by the Member States under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD)

(Official Journal of the European Union L 279 of 31 October 2019)

In the Annex, on page 110, in the table concerning Budget Item: 6 7 0 1, the last line of the entry concerning the United Kingdom of Great Britain and Northern Ireland:

for:

| ‘Total GB: | EUR | -2 405 802,18 | -3 894,02 | -240 908,16 ’ |
| --- | --- | --- | --- | --- |

‘Total GB:

EUR

-2 405 802,18

-3 894,02

-240 908,16 ’

read:

| ‘Total GB: | EUR | -2 405 802,18 | -3 894,02 | -2 401 908,16 ’ |
| --- | --- | --- | --- | --- |

‘Total GB:

EUR

-2 405 802,18

-3 894,02

-2 401 908,16 ’

---
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                         322,952
<SECURITIES>                                         0
<RECEIVABLES>                                  478,417
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      32,953,290
<DEPRECIATION>                              18,267,003
<TOTAL-ASSETS>                              30,226,309
<CURRENT-LIABILITIES>                        1,259,768
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                (10,857,266)
<TOTAL-LIABILITY-AND-EQUITY>                30,226,309
<SALES>                                      8,999,858
<TOTAL-REVENUES>                             8,999,858
<CGS>                                        7,623,501
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,665,389
<INCOME-PRETAX>                              (360,786)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (360,786)
<EPS-BASIC>                                        0
<EPS-DILUTED>                                        0


</TABLE>
<PAGE>   1

                                   EXHIBIT 5.1


                               OPINION OF COUNSEL

         I have acted as counsel for Ride, Inc., a Washington corporation (the
"Company"), in connection with the preparation and filing of this Registration
Statement on Form S-3 (the "Registration Statement"), under the Securities Act
of 1933, as amended. The Registration Statement covers 2,832,573 shares of
Common Stock, no par value, of the Company plus such indeterminate number of 
shares of Common Stock as may become issuable upon conversion or exercise of 
certain convertible preferred stock and warrants as a result of future stock
splits, stock dividends or similar events (collectively, the "Stock"), 
which may be sold by the "Selling Shareholders".

         As General Counsel for the Company, I have reviewed the corporate
actions of the Company in connection with this matter and have examined the
documents, corporate records and other instruments deemed necessary for the
purpose of this opinion.

         Based on the foregoing, it is my opinion that:

         (I) The Company is a corporation duly incorporated and validly existing
under the laws of the State of Washington; and

         (II) The Stock being registered has been duly authorized and validly
issued and is fully paid and nonassessable.

         I consent to the filing of this opinion as Exhibit 5.1 to the
Registration Statement and to the reference to me under the caption "Legal
Matters" in the Prospectus which is part of the Registration Statement.


January 21, 1998



/s/ David H. Davis 
-------------------------------
David H. Davis, General Counsel
and Corporate Secretary
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 1316 Introduced in Senate (IS)]

<DOC>

115th CONGRESS
  1st Session
                                S. 1316

   To amend title 10, United States Code, to provide for a one-year 
  extension of the suicide prevention and resilience program for the 
                      National Guard and Reserves.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              June 8, 2017

Mrs. Ernst (for herself and Mr. Tester) introduced the following bill; 
  which was read twice and referred to the Committee on Armed Services

_______________________________________________________________________

                                 A BILL

 
   To amend title 10, United States Code, to provide for a one-year 
  extension of the suicide prevention and resilience program for the 
                      National Guard and Reserves.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ONE-YEAR EXTENSION OF SUICIDE PREVENTION AND RESILIENCE 
              PROGRAM FOR THE NATIONAL GUARD AND RESERVES.

    Section 10219(g) of title 10, United States Code, is amended by 
striking ``October 1, 2018'' and inserting ``October 1, 2019''.
                                 <all>
```
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEETS OF NEORX CORPORATION AS OF 09/30/98 AND 12/31/97 AND THE RELATED
STATEMENTS OF OPERATIONS FOR EACH OF THE 9 MONTHS ENDED 09/30/98 AND 09/30/97
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 10-Q REPORT FOR THE PERIOD
ENDED 09/30/98.
</LEGEND>
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                            1798
<SECURITIES>                                     30786
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 33466
<PP&E>                                            7925
<DEPRECIATION>                                    6890
<TOTAL-ASSETS>                                   34973
<CURRENT-LIABILITIES>                             1630
<BONDS>                                           1195
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          4
<COMMON>                                           420
<OTHER-SE>                                       31724
<TOTAL-LIABILITY-AND-EQUITY>                     34973
<SALES>                                              0
<TOTAL-REVENUES>                                  7697
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  98
<INCOME-PRETAX>                                 (1405)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             (1405)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    (1405)
<EPS-PRIMARY>                                    (.09)
<EPS-DILUTED>                                    (.09)
        

</TABLE>
Exhibit 99.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In
connection with the Quarterly Report of Southwall Technologies Inc. (the "Company") on Form 10-Q for the period ending June 30, 2002 as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), I, Thomas G. Hood, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant
§ 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)  The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  The
information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

|/s/THOMAS G. HOODThomas G. Hood
Chief Executive Officer
August 13, 2002 |  | 
|----------------------------------------------------------------------- |  | 

This
Certification is made solely pursuant to the Sarbanes-Oxley Act of 2002 and shall not be deemed part of the Report or incorporated by reference into any of the Company's filings with the
Securities and Exchange Commission by implication or by any reference in any such filings to the Report.

---

QuickLinks
### Michigan Supreme Court Lansing, Michigan

Marilyn Kelly, Chief Justice

Michael F. Cavanag h
Elizabeth A. Weave r

Maura D. Corriga n Robert P. Young, Jr. Stephen J. Markma n Diane M. Hathaway,
J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk January 29, 2010

0125 

# Order

January 29, 2010

139393

ROBERT J. ROOSENBERG, M.D., Plaintiff-Appellant,

v SC: 139393 COA: 280235 Kent CC: 04-003796-NM JAMES ZERRENNER and ZERRENNER & ROANE, Defendants-Appellees.

________________ _______________ __________/

On order of the Court, the applicati on for leave to appeal the May 5, 2009 judgment of the Court of Appeals is consid ered, and it is DENIED, because we are not persuaded that the questions presented should be reviewed by this Court.
§ 182.3280 Dilauryl thiodipropionate. ( a ) *Product.* Dilauryl thiodipropionate.
( b ) *Tolerance.* This substance is generally recognized as safe for use in food when the total content of antioxidants is not over 0.02 percent of fat or oil content, including essential (volatile) oil content of the food, provided the substance is used in accordance with good manufacturing practice.
#### § 21.60 Policy.

It is the policy of the Food and Drug Administration that record systems should be exempted from the Privacy Act only to the extent essential to the performance of law enforcement functions under the laws that are administered and enforced by the Food and Drug Administration or that govern the agency.
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.

, Chief Justice

Stephen J. Markman

Mary Be th Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

Richard H. Bernstein,

Justices

I, Larry S. Royster , Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

July 2, 2015

s0630 

# Order

Clerk July 2, 2015

150957

BANK OF NEW YORK MELLON, f/k/a BANK

OF NEW YORK, as Trustee for the Certificate

Holders of CWABS, INC., ASSET

- BACKED

CERTIFICATES SERIES 2003

- 3,

Plaintiff

- Appellant,

v SC: 150957

COA: 316521

Wayne CC: 11

- 008424

- CH

JAAFAR K. JAAFAR and BADIA JAAFAR,

Defendants

- Appellees.

_________________________________________/

On order of the Court, the application for leave to appeal the December 23, 2014

judgment of the Court of Appeals is considered and, pursuant to MCR 7.302(H)(1), in

lieu of granting leave to appeal, we REVERSE the judgment of the Court of Appeals.

An offer “is the manifestatio n of willingness to enter into a bargain, so made as to

justify another person in understanding that his assent to that bargain is invited and will

conclude it.” See Eerdmans v Maki , 226 Mich App 360, 364 (1997). Here, and contrary

to the judgment of the Court of Appeals, the January 20, 2012 e

- mail from plaintiff’s

counsel to defendants’ counsel did not constitute an offer to settle this case. Instead, this

e

- mail inquired whether defendants would present an offer at some point in the future,

which they did, through a subsequent e

- mail by their counsel. Defendants’ counsel

confirmed that this subsequent e

- mail was an offer by later inquiring whether plaintiff

had accepted their offer. For these reasons, and for the reasons stated by the Court of

Appeal s’ dissenting opinion, no enforceable settlement agreement existed to bind the

parties in this case. We REMAND this case to the Wayne Circuit Court for further

proceedings not inconsistent with this order.

We do not retain jurisdiction.
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.6 Labeling of an investigational new drug. ( a ) The immediate package of an investigational new drug intended for human use shall bear a label with the statement “Caution: New Drug—Limited by Federal (or United States) law to investigational use.”
( b ) The label or labeling of an investigational new drug shall not bear any statement that is false or misleading in any particular and shall not represent that the investigational new drug is safe or effective for the purposes for which it is being investigated.
( c ) The appropriate FDA Center Director, according to the procedures set forth in §§ 201.26 or 610.68 of this chapter, may grant an exception or alternative to the provision in paragraph (a) of this section, to the extent that this provision is not explicitly required by statute, for specified lots, batches, or other units of a human drug product that is or will be included in the Strategic National Stockpile.
[52 FR 8831, Mar. 19, 1987, as amended at 72 FR 73599, Dec. 28, 2007]
§ 1309.51 Hearings generally. ( a ) In any case where the Administrator shall hold a hearing on any registration or application therefore, the procedures for such hearing shall be governed generally by the adjudication procedures set forth in the Administrative Procedure Act (5 U.S.C. 551-559) and specifically by sections 303 and 304 of the Act (21 U.S.C. 823-824), by §§ 1309.52 through 1309.55, and by the procedures for administrative hearings under the Act set forth in §§ 1316.41 through 1316.67 of this chapter.
( b ) Any hearing under this part shall be independent of, and not in lieu of, criminal prosecutions or other proceedings under the Act or any other law of the United States.
[60 FR 32454, June 22, 1995, as amended at 81 FR 97021, Dec. 30, 2016]
§ 120.10 Corrective actions. Whenever a deviation from a critical limit occurs, a processor shall take corrective action by following the procedures set forth in paragraph (a) or paragraph (b) of this section. ( a ) Processors may develop written corrective action plans, which become part of their HACCP plans in accordance with § 120.8(b)(5), by which processors predetermine the corrective actions that they will take whenever there is a deviation from a critical limit. A corrective action plan that is appropriate for a particular deviation is one that describes the steps to be taken and assigns responsibility for taking those steps, to ensure that: ( 1 ) No product enters commerce that is either injurious to health or is otherwise adulterated as a result of the deviation; and
( 2 ) The cause of the deviation is corrected.
( b ) When a deviation from a critical limit occurs, and the processor does not have a corrective action plan that is appropriate for that deviation, the processor shall: ( 1 ) Segregate and hold the affected product, at least until the requirements of paragraphs (b)(2) and (b)(3) of this section are met;
( 2 ) Perform or obtain a review to determine the acceptability of the affected product for distribution. The review shall be performed by an individual or individuals who have adequate training or experience to perform such review;
( 3 ) Take corrective action, when necessary, with respect to the affected product to ensure that no product enters commerce that is either injurious to health or is otherwise adulterated as a result of the deviation;
( 4 ) Take corrective action, when necessary, to correct the cause of the deviation; and
( 5 ) Perform or obtain timely verification in accordance with § 120.11, by an individual or individuals who have been trained in accordance with § 120.13, to determine whether modification of the HACCP plan is required to reduce the risk of recurrence of the deviation, and to modify the HACCP plan as necessary.
( c ) All corrective actions taken in accordance with this section shall be fully documented in records that are subject to verification in accordance with § 120.11(a)(1)(iv)(B) and the recordkeeping requirements of § 120.12.